Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL143637 | 1.00 | NR1H4 (0.50) | NR1H4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL138677 | 0.90 | NR1H4 (0.49) | NR1H4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL138676 | 0.90 | NR1H4 (0.49) | NR1H4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL178749 | 0.82 | NPC1 (0.47) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL13756220 | 0.82 | NPC1 (0.47) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL5242234 | 0.77 | ALDH1A1 (0.50) | NR1H4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL27885919 | 0.77 | NR1H4 (0.43) | NR1H4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL29282944 | 0.76 | NR1H4 (0.67) | NR1H4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL20401024 | 0.74 | TDP1 (0.62) | KMT2ANPC1RAB9ALMNAALDH1A1 | |
| SCHEMBL9726818 | 0.74 | MEN1 (0.87) | NR1H4MEN1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408080-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | PFIZER IRELAND PHARMACEUTICALS | 2024-12-12 | — | — | US | disclosed |
| EP-4284505-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | Pfizer Ireland Pharmaceuticals (IE) | 2023-12-06 | — | — | EP | disclosed |
| US-20220401439-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2022-12-22 | — | — | US | disclosed |
| EP-4076395-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-114980862-A | Intranasal pharmaceutical compositions of CGRP inhibitors | 拜尔哈文制药股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2022165291-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-08-04 | — | — | WO | disclosed |
| WO-2021127070-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-2552906-B1 | CGRP RECEPTOR ANTAGONIST | BRISTOL MYERS SQUIBB CO (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8481546-B2 | CGRP receptor antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2552906-A1 | CGRP RECEPTOR ANTAGONIST | Bristol-Myers Squibb Company (US) | 2013-02-06 | — | — | EP | disclosed |
| US-20120059017-A1 | CGRP Receptor Antagonist | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| WO-2011123232-A1 | CGRP RECEPTOR ANTAGONIST | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-06 | — | — | WO | disclosed |
| US-7449586-B2 | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| CN-1914193-A | Heterocyclic antimigraine agents | BRISTOL MYERS SQUIBB CO (US) | 2007-02-14 | — | — | CN | disclosed |
| WO-2006060678-A2 | NOVEL PROCESSES FOR THE PREPARATION OF CGRP-RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060122250-A1 | Novel processes for the preparation of CGRP-receptor antagonists and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401439-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | CALCA, CALCB, CALCRL | NR1H4 2881/4885MEN1 655/4885KMT2A 4746/4885 |
| US-20240408080-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | CALCA, CALCB, CALCRL | NR1H4 2459/4885MEN1 1092/4885KMT2A 4777/4885 |
| US-20060122250-A1 | Novel processes for the preparation of CGRP-receptor antagonists and intermediates thereof | CALCR, CALCRL, CALCB | NR1H4 482/4885MEN1 1206/4885KMT2A 4762/4885 |
| US-20120059017-A1 | CGRP Receptor Antagonist | CALCRL, PTGIR, CALCR | NR1H4 1350/4885MEN1 1576/4885KMT2A 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.